Your search returned 2 results.

Sort
Unhighlight Highlight
Select all Clear all
Select titles to:
Results
1.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 27284114
Year: 2016
Citation:
  • Diabetes Care. 39(9):1579-86, 2016 Sep
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
DOI:
Add to cart
2.
Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 31359368
Year: 2019
Citation:
  • Advances in Therapy. 36(9):2310-2326, 2019 09.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Bailey TS, Blonde L, Chao J, Dex TA, Frias JP, Meneghini LF, Roberts M
DOI:
Add to cart
Pages

Powered by Koha